{"created":"2023-12-15T00:44:02.960533+00:00","id":2000010,"links":{},"metadata":{"_buckets":{"deposit":"f95c341f-4e64-426f-9297-d4916cfcb317"},"_deposit":{"created_by":4,"id":"2000010","owner":"4","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"2000010"},"status":"published"},"_oai":{"id":"oai:kawasakigakuen.repo.nii.ac.jp:02000010","sets":["33:1702524861011"]},"author_link":["314","168","380","65","66","46","67","57","35"],"control_number":"2000010","item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2023-11-30","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicNumberOfPages":"13","bibliographicPageEnd":"71","bibliographicPageStart":"59","bibliographicVolumeNumber":"4","bibliographic_titles":[{"bibliographic_title":"COGNITION & REHABILITATION","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"In June 2021, the United States Food and Drug Administration granted accelerated approval for aducanumab, the first monoclonal antibody drug to be used in clinical settings in the United States. Meanwhile, it has not received approval in Europe or in Japan owing to significant reduction of amyloid beta without evidence of slowing down the progression of cognitive decline of patients with early Alzheimer disease. In January 2023, outine approval was granted in the United States for a second antibody, lecanemab, which had sufficient evidence of clinical effect and significant deprivation of amyloid beta in the phase 3 trials. Lecanemab was pproved by the Japanese regulatory authorities in Japan in September 2023 after Eisai filed for approval in January. A framework for treatment of Alzheimer disease with antibody therapeutics is required. Although lecanemab has emonstrated efficacy, side effects including amyloid-related imaging abnormality have also been confirmed. Based on the results of clinical trials, there is ongoing discussion of the system for its use in clinical settings. ecanemab is expected to have disease-modifying effects and may inhibit the rate of cognitive decline in the early stage of Alzheimer disease, thereby prolonging the duration of mild stage period. This is also the period hen the rehabilitation is most effective, making psychosocial interventions more important than ever. Rehabilitation techniques need to be developed for patients with early Alzheimer disease receiving disease-modifying therapy. Although disease-modifying drugs inhibit the progression of symptoms in the early stages for a certain period of time, once the threshold is exceeded, cognitive function may decline more rapidly than in non-drug-treated individuals. From this perspective, the effects of disease-modifying therapy are analogous to the effect of high cognitive reserve. These considerations should be taken into account to enhance the clinical utility of rehabilitation for patients under disease-modifying therapy for Alzheimer disease.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10001_description_6":{"attribute_name":"内容種別","attribute_value_mlt":[{"subitem_description":"Review Article","subitem_description_language":"en","subitem_description_type":"Other"}]},"item_10001_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.69202/0002000010","subitem_identifier_reg_type":"JaLC"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Osaka Kawasaki Rehabilitation University","subitem_publisher_language":"en"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2436-1097","subitem_source_identifier_type":"PISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Masatoshi TAKEDA","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"314","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Misa NAKAMURA","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"168","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hirotoshi UTSUNOMIYA","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"380","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Tatsunori MURAKAMI","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"65","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Junya SAEKI","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"66","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takanari KUBO","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"46","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yuya NAKAGOSHI","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"67","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nobuo OSHIMA","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"57","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Keiko SAKAI","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"35","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2023-12-15"}],"filename":"p59-71_Masatoshi TAKEDA.pdf","filesize":[{"value":"975 KB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"url":"https://kawasakigakuen.repo.nii.ac.jp/record/2000010/files/p59-71_Masatoshi TAKEDA.pdf"},"version_id":"7343f94e-c351-4262-805c-8eadc51b4551"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Alzheimer disease","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"immunotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"disease-modifying therapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"aducanumab","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"lecanemab","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"donanemab","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"rehabilitation","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"review article","resourceuri":"http://purl.org/coar/resource_type/c_dcae04bc"}]},"item_title":"Implementation of monoclonal antibody therapy and new rehabilitation strategies for Alzheimer disease","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Implementation of monoclonal antibody therapy and new rehabilitation strategies for Alzheimer disease","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"4","path":["1702524861011"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2023-12-15"},"publish_date":"2023-12-15","publish_status":"0","recid":"2000010","relation_version_is_last":true,"title":["Implementation of monoclonal antibody therapy and new rehabilitation strategies for Alzheimer disease"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2024-09-25T01:45:12.571567+00:00"}